Results 231 to 240 of about 125,062 (284)

Selective RyR2 inhibition reduces arrhythmia susceptibility in human cardiac slices

open access: yesThe Journal of Physiology, Volume 604, Issue 5, Page 1809-1819, 1 March 2026.
Abstract figure legend ent‐Vert selectively inhibits RyR2‐mediated sarcoplasmic reticulum (SR) Ca2+ leak and prevents triggered activity in human cardiac slices. A, in human ventricular slices exposed to β‐adrenergic stimulation with Iso and RyR2 sensitization with caffeine, RyR2 channels become hyperactive, leading to Ca2+ sarcoplasmic leak and ...
Micah K. Madrid   +6 more
wiley   +1 more source

Non‐invasive cardiac power measurements in decompensated heart failure in elderly adults: A prospective proof‐of‐concept study

open access: yesPhysiological Reports, Volume 14, Issue 6, March 2026.
Abstract In this proof‐of‐concept study, we evaluated the feasibility of non‐invasive estimation of cardiac power metrics—total power, steady power, oscillatory power, and oscillatory power fraction—and compared the prognostic and diagnostic value with established echocardiographic metrics. We prospectively included 29 patients (mean age 76 ± 13 years,
Ingrid Yttervoll   +5 more
wiley   +1 more source

Bridging innovation and access: integrating cardiac amyloidosis into health system strengthening in the Americas. [PDF]

open access: yesLancet Reg Health Am
Zavaleta-Monestel E   +3 more
europepmc   +1 more source

Alpha‐Actinin‐3 Deficiency Links Genetic Susceptibility to Renal Fibrosis: Evidence From Hemodialysis Patients and Murine Models

open access: yesThe FASEB Journal, Volume 40, Issue 4, 28 February 2026.
This study links the ACTN3 R577X polymorphism to chronic kidney disease (CKD), specifically in patients undergoing hemodialysis (HD). In parallel, increased Actn3 expression in murine models of kidney injury supports a functional role for ACTN3 in renal pathophysiology.
Raisa B. Santos   +13 more
wiley   +1 more source

Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients. [PDF]

open access: yesHemasphere
Bellofiore C   +17 more
europepmc   +1 more source

Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis. [PDF]

open access: yesJACC CardioOncol
Sideris K   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy